Clinical Trials

The purpose of this study is to evaluate the prevalence and effect of frailty in patients referred to pulmonary hypertension (PH) clinic at our institution.

The purpose of this study is to see if patients with Pulmonary Arterial Hypertension related to Interstitial Lung Disease (ILD-PAH) will have impaired cardiac output reserve and leg blood flow during exercise, and inhlaed treprostinil will acutely increase exertional leg blood flow and cardiac output with preserved skeletal muscle O2 uptake efficiency, and to see a baseline hemodynamic improvement in exertional cardiac output with inhaled treprostinil will predict subsequent NYHA class improvement at 3 months with chronic inhaled treprostinil therapy.

The purpose of this study is to evaluate the effects of RT234 on exercise parameters assessed by a specialized exercise test (Cardiopulmonary Exercise Test or CPET) in patients with pulmonary arterial hypertension (PAH).

The purpose of this study is to assess the effect of Treprostinil Palmitil Inhalation Powder (TPIP) compared with placebo on pulmonary vascular resistance (PVR).

The purpose of this study is to collect pulmonary arterial endothelial cells from the balloon tips of pulmonary artery catheters (PAC) during right heart catheterization (RHC) and to measure bcl-2 protein expression in these cells in order to index this measurement to a composite hemodynamic and clinical indicators of precapillary vascular disease in pulmonary hypertension. 

The purpose of this study is to evaluate the long-term safety and tolerability of ralinepag (APD811) in subjects who have participated in a preceding Phase 2 or Phase 3 study of ralinepag.  MCF will not participate in the PK Substudy.

The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).

The purpose of this study is to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk distance (6MWD) after 24 weeks of treatment.

The purpose of this study is to assess the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary arterial hypertension.

The purpose of the United States Pulmonary Hypertension Scientific Registry (USPHSR) will be to promote a greater understanding of PAH in an era of genetic discoveries, the study of the physical make up of individual people, and new treatments through education and collaborative assessment of information among pulmonary hypertension (PH) centers throughout the U.S. The development of a national USPHSR Registry will be an important element for advancement of the understanding of PAH and improvement of the care of patients who suffer from this life threatening disorder.

The primary objective of this study is to evaluate the effect of selexipag on pulmonary vascular resistance (PVR) versus placebo in subjects with inoperable CTEPH (i.e., technically non-operable) and persistent/recurrent CTEPH after surgical (pulmonary endarterectomy [PEA]) and/or interventional (balloon pulmonary angioplasty [BPA] treatment at Week 20.

The secondary objectives are to evaluate the effects of selexipag versus placebo on exercise capacity, rate of death or hospitalizations related to Pulmonary Hypertension (PH) worsening, time to clinical worsening, WHO functional class (FC), patient reported outcomes, dyspnea, and N-terminal pro b-type natriuretic peptide (NT-proBNP).

The purpose of this extension study is to provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.

Pulmonary hypertension (PH) is a progressive, symptomatic, and ultimately fatal disorder for which there are no effective therapies. Resident gut microbiota are now recognized as potent modifiers of the host immune responses in various pathologies. Evidence from animal studies suggest that the microbial composition is altered in lung diseases such as asthma, chronic obstructive pulmonary disorders (COPD) and cystic fibrosis. Our goal in this study will be to determine and compare the gut microbial composition between healthy individuals and pulmonary hypertensive patients.

The purpose of this study is to establish a collection, termed biorepository or biobank, of samples as well as both clinical and genetic data from patients with pulmonary arterial hypertension.

STUDY OBJECTIVES Primary objective(s) To evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation.

Secondary objectives To evaluate the effect of macitentan 10 mg as compared to placebo on cardio-pulmonary hemodynamics and disease severity in subjects with PH after LVAD implantation.

To evaluate the safety and tolerability of macitentan 10 mg in subjects with PH after LVAD implantation.

Exploratory objectives To explore the potential effect of macitentan 10 mg as compared to placebo on right ventricular function ...

The purpose of this study is to:

1. To assess out of pocket expenditures of patients on medical therapy for Group 1 PAH, its impact on medication affordability and whether that adversely affected treatment regimens.

2. To analyze potential effects associated with the financial burden of PAH medical therapy.

3. The secondary outcome is to assess the impact of pulmonary arterial hypertension on healthy lifestyle of the patients.

The purpose of this study is to compare the effectiveness and safety of three (macitentan, tadalafil, and selexipag) versus two (macitentan and tadalafil) oral treatments for patients who have newly diagnosed and untreated hypertension of the pulmonary artery.

The purpose of this study is to evaluate the effectiveness and safety of Sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with Pulmonary Arterial Hypertension (PAH).

The purpose of this study is to assess the long-term safety, tolerability, and effectiveness of sotatercept in Pulmonary Arterial Hypertension (PAH).

The purpose of this study is to characterize the clinical and hemodynamic response of PAH therapy in patients with atypical PAH and risk factors for left heart disease.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).

The purpose of this study is to evaluate the diagnostic benefit of adding exercise to cardiac Magnetic Resonance Imaging to help show early changes that may assist in the earlier diagnosis of Pulmonary Artery Hypertension.

The primary purpose of this study is to identify and develop biomarker signatures based on circulating micro ribonucleic acid (RNA) in the blood and on exhaled volatile organic compounds (VOC) in the breath associated with high risk of pulmonary hypertension (PH) to assist in the diagnosis of PH; to estimate the sensitivity, specificity, positive predictive value, and negative predictive value of the biomarker signatures in identifying participants with PH by comparing the biomarker signatures to right heart catheterization (RHC) and to compare the sensitivity, specificity, positive predictive value, and negative predictive value of the biomarker signatures with the sensitivity, specificity, ...

The purpose of this study is to assess the effectiveness and safety of Selexipag in subjects with inoperable or persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH).  

The purpose of this study is to evaluate the Pulmonary Hypertension Functional Class Self Report (PHFC-SR) ratings for a sample of subjects with pulmonary hypertension (PH).

A secondary purpose is to explore the concordance between the patient-reported PH-FC-SR and clinician-assessed World Health Organization Functional Classification (WHO-FC) measure in a sample of subjects with PH, and to assess the construct validity between the patient-reported PH-FC-SR and a patient-reported disease-specific measure and a general health-related quality of life (HRQOL) measure.

The primary objective of this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.

The secondary objective is to determine the effect of GB002 on improving exercise capacity in this population.

The purpose of this study is to evaluate the effect of macitentan 10 mg on pulmonary vascular resistance as compared to placebo in subjects with pulmonary hypertension after left ventricular assist device (LVAD) implantation

The purpose of this study is to determine if non-invasive measurement of blood flow to the lungs and the movement of gas from the lungs to the blood stream at rest and in response to low to moderate intensity exercise can be used as an assessment tool to allow for earlier detection and monitoring of individuals with pulmonary-arterial hypertension, and the response to drug treatments.

The purpose of this study is to describe the time to all-cause death and time to death due to pulmonary arterial hypertension (PAH) or first hospitalization due to PAH in the overall study population and within each cohort.

The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH). A secondary objective of this study is to evaluate the comparative bioavailability of treprostinil between two formulations of inhaled therapy.

The purpose of this study is to assess known gene variants in a patient with associated pulmonary arterial hypertension (PAH) due to scleroderma who is clinically vasoreactive to compare to published variants that are predictive of acute vasoreactivity in idiopathic PAH.
 

We propose to develop a biorepository of plasma samples from patients with suspected and confirmed portopulmonary hypertension to improve our understanding of this disease and its response to pulmonary arterial hypertension targeted therapy and liver transplantation.

The purpose of this study is to evaluate the effect of sotatercept (ACE-011) in adults with Pulmonary Arterial Hypertension. Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24 week treatment period followed by a 16 week follow up period.

The primary purpose of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH). A secondary objective of this study is to evaluate the comparative bioavailability of treprostinil between two formulations of inhaled therapy.

The purpose of this study is to demonstrate the safety and tolerability of repeated doses of L606 in patients with PAH switching from a stable Tyvaso dose. The current Phase 3 study will help determine the short-term and long-term safety and tolerability of L606 in this patient population. The study will also evaluate the steady-state  pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise ability (6-minute walk distance [6MWD] and Borg Dyspnea Score), quality of life (QoL), and treatment satisfaction with L606 in patients with PAH.

Part 1 of the study is short-term (2-week) evaluation of L606 in patients with PAH. Part 2 of the study will ...

The International Balloon Pulmonary Angioplasty (BPA) Registry is a prospective, multi-center, long-term observational project. Scheduled to start data collection in Q4 2017, the registry will run for approximately four years with a follow-up time for each patient of at least two years. Its primary objective is to investigate the efficacy and safety of BPA intervention in patients with chronic thromboembolic pulmonary hypertension (CTEPH) not amenable to pulmonary endarterectomy (PEA).

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of ubenimex in patients who have pulmonary arterial hypertension, to improve exercise capacity and delay clinical worsening.

The purpose of this study is to identify, characterize, and study a group of patients who have pulmonary hypertension, newly diagnosed in the current treatment era, when investigators can use the contributions of genomics and clinical imaging tests to further understand the disease. This registry should advance knowledge in the field both from a molecular (genomic and proteomic) and from a clinical phenotype standpoint.

The purpose of this study is to evaluate pulmonary arterial hypertension (PAH) subjects on a stable regimen of Tyvaso after switching to a corresponding dose of TreT.

The purpose of this study is to evaluate the effect of Rodatristat Ethyl from baseline on pulmonary vascular resistance as measured at right heart catheterization. 

This is a prospective, multicenter, open-label, randomized, controlled, parallel group, group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and pharmacokinetics (PK) of macitentan in children.

The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH). A secondary objective of this study is to evaluate the comparative bioavailability of treprostinil between two formulations of inhaled therapy.

The purpose of this study is to identify the molecular basis of various forms of heart and lung disease, particularly those that have varying degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular dysfunction.

The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with pulmonary arterial hypertension (PAH).

The goals of the PHAR include 1) measuring and improving quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes), 2) determining the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understanding risk factors for outcomes and regional/center differences, and 4) facilitating funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers.

The purpose of this extension study is to evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

The objectives of this study are to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes); determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches; understand risk factors for outcomes and regional/center differences; and facilitate funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers.

This study will compare the efficacy, safety, and tolerability of three doses of GS-4997 to placebo in adults with pulmonary arterial hypertension (PAH). The study will consist of a 24-week placebo-controlled treatment period and a long-term GS-4997 treatment period. Participants completing the 24-week placebo-controlled period will be eligible to receive active treatment with GS-4997 in the long-term treatment period.

The PHAR is a multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH.  Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.

The specific purpose of this study is to establish a national biorepository of biological samples and genetic data of patients with the World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH).   The function of this biorepository is to collect the samples from the patients, generate the proposed genetic data, and widely promote and distribute the samples/data to the scientific community.  Investigators requesting samples will submit requests and proposed uses of the samples which will be reviewed by a committee comprised of investigators from several of the enrolling centers.

The purposes of this study is to estimate the freedom from catheter-related complications through 5 years post-implant and to estimate the freedom from ISR pump failures through 5 years post- implant.

The aim of this study is to evaluate the effects of a home-based program with health coaching of dyspnea and exercieses in subjects with pulmonary arterial hypertension (PAH).

Pulmonary rehabiltation has been shown to be an effective treatment for patients with chronic obstructive pulmonary disease, however there is currently a paucity of evidence to extrapolate this informaiton with patients with pulmonary arterial hypertension (PAH). In addition, there are no options outside of center-based pulmonary rehabilitation which have been proposed as an effective treatment option for patients with PAH.

The primary purpose of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in WHO functional class.

The U.S. CTEPH Registry is a multicenter, observational, U.S.-based study of the clinical course and treatment of patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension. The mission of the Registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of patients with CTEPH through shared information, education, and collaborative investigation among pulmonary hypertension (PH) centers of excellence throughout the U.S.

The purpose of this study is to evaluate the long-term safety, tolerability, and effectiveness of ubenimex for the treatment of patients who have pulmonary arterial hypertension, to improve exercise capacity and delay clinical worsening.

To evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH

The purpose of this study is to demonstrate the effect of ralinepag the time to first adjudicated clinical worsening event in subjects with pulmonary arterial hypertension (PAH).Clinical worsening event is defined as 1 of the following: death, nonelective hospital admission of <24 hours="" due="" to="" worsening="" pah="" or="" rhf,="" initiation="" of="" parenteral="" or="" inhaled="" therapy,="" disease="" progression,="" or="" unsatisfactory="" long="" term="" clinical="">

The purpose of this study is to establish the long-term safety of AV-101. The long-term effects of AV-101 on efficacy measures (e.g., 6MWD, NT-proBNP, cardiac echo) will also be assessed.

The primary purpose of this study is to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes).

The primary purpose of this study is to demonstrate the safety and effectiveness of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic response.

The purpose of this study is to form a registry to follow patients with sarcoidosis associated pulmonary hypertension

The purposed of this study are to investigate whether structured exercise training improves cardiac and pulmonary haemodynamic function, exercise capacity, and short-term clinical outcomes in heart failure (HF) patients with Pulmonary Hypertension (PH), and to develop a multivariable exercise pulmonary gas exchange ‘score’ that accurately differentiates HF patients with pre- and post-capillary PH (CpcPH) from HF patients with isolated post-capillary PH (IpcPH).

The purpose of this study is to evaluate the effectiveness and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects.

The purpose of this study is to determine the association between patient voice signal characteristics and the presence and severity of pulmonary hypertension in patients referred for elective clinically indicated echocardiography for at Mayo Clinic MN.

The purpose of this study is to evaluate the effectiveness and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Effectiveness is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

The purpose of this study is to assess the safety and efffectiveness of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy.

The primary purpose of this study is to administer the PAH SYMPACT questionnaire in 200 consecutive eligible patients attending the Mayo Clinic pulmonary hypertension clinic. An additional patient satisfaction survey will be administered for patients that completed a palliative care consult.

The purpose of this study is to evaluate for safety and effectiveness weekly, open-label doses of levosimendan over extended use in patients with pulmonary hypertension with heart failure and preserved left ventricular ejection fraction (PH-HFpEF).

24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

The aims of this study are to establish a registry and biorepository of patients with PH-CKD, and to identify clinical risk factors and biomarkers associated with PH-CKD and different hemodynamic phenotypes. 

This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left ventricular ejection fraction (LVEF) <0.40, and secondary pulmonary hypertension (PH). The purpose of the study is to evaluate the safety, effectiveness, and effects of tadalafil compared to placebo on the subjects' functional capacity / quality of life.

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects will take the initial dose of study drug at the study site on the day of randomization. Subjects will return to the study site for visits scheduled at Weeks 6, 12, 18, and 24. The treatment phase of the study will last approximately 24 weeks.

This is an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who have completed Study TDE-HF-301. This study will provide long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits will occur at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil becomes commercially available to treat PH associated with HFpEF or the study is discontinued by the Sponsor.

The enormous and rapidly growing burden of Heart Failure with Preserved Ejection Fraction (HFpEF) has led to a need to understand the pathogenesis and treatment options for this morbid disease. Recent research from the investigator's group and others have shown that pulmonary hypertension (PH) is highly prevalent in HFpEF, and right ventricular (RV) dysfunction is present in both early and advanced stages of HFpEF.

These abnormalities in the RV and pulmonary vasculature are coupled with limitations in pulmonary vasodilation during exercise. There are no therapies directly targeted at the pulmonary vasculature that have been clearly shown to be effective ...

The purpose of this open-label study is to evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the  and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

The purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome.

SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension. Patients will be in the study for 5 1/2 months, 4 months of which they will receive macitentan, 10 mg, once daily.

The primary objectives are to demonstrate the final content validity of the PAH SYMPACT instrument, to demonstrate the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT instrument, and to demonstrate the ability of the PAH SYMPACT instrument to detect change. The secondary objective is to assess the safety of macitentan in ...

The purpose of this study is toexamine whether increased sphingosine 1 phosphate : ceramide ratio and circulating bile acids are associated with HPS in patients with advanced liver disease.

The purpose of this study is to assess whether our not the percentage of pulmonary related vascular structures (PRVS) determined by the quantitative CT (Q-CT) tool CALIPER is a novel measure that can be used for the early detection of pulmonary vascular remodeling in patients with SSc.  pulmonary related vascular structures

A surveillance of respiratory tract related adverse events in patients treated with Tyvaso® (treprostinil) Inhalation Solution versus other FDA approved therapies.

We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.

This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available ...

Systolic Pressure Intervention Trial (SPRINT) is a large scale randomized trial of ~ 9250 adults aged 50 years or older with high cardiovascular risk sponsored by NIH. The study is designed to recruit 45% of the study population with Chronic Kidney Disease (CKD). The trial will test the effects of low systolic blood pressure (SBP) goal of < 120 mm Hg versus the standard goal of < 140 mm Hg on the primary composite of cardiovascular events and death. One of the pre-specified secondary outcome is the progression of kidney disease. In this ancillary named SPRINT - Factors affecting Atherosclerosis ...

The purpose is to study the correlation of right ventricular strain by tissue Doppler and Tricuspid Annular Plane Systolic Excursion (TAPSE) in patients without a tricuspid regurgitation jet with the presence and severity of pulmonary artery hypertension diagnosed by right heart catheterization. The primary aim is to determine the correlation of other echocardiographic, laboratory and clinical findings in patients without a tricuspid regurgitation jet with the presence and severity of pulmonary artery hypertension diagnosed by right heart catheterization. As such, one goal is to potentially create a predictive score with adequate sensitivity to determine which patients without a tricuspid regurgitation ...

The purpose of  this study is to determine the usefulness of palliative care consultations by a specialty physician and a pulmonologist for patients who have advanced lung disease.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).

The purpose of this study is to determine if vasodilators for the lungs can decrease liver stiffness, shown by Magnetic resonance elastography (MRE).  The study also aims to identify any clinical, laboratory, echocardiographic, imaging, and hemodynamic parameters that connect with improved outcomes of cardiac and liver status after starting the pulmonary vasodilators.

The eventual goal of this study is to identify genetic and proteomic markers that may influence susceptibility to vascular diseases including peripheral arterial disease, pulmonary hypertension, carotid artery stenosis, arterial aneurysmal disease, fibromuscular dysplasia, congenital heart disease and other less common diseases that affect the blood vessels.

The purpose of this study is to evaluate the effietiveness of remdesivir (RDV) in reducing the rate of of all-cause medically attended visits (MAVs; medical visits attended in person by the participant and a health care professional) or death in non-hospitalized participants with early stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in an outpatient setting.